Astellas, Medivation's cancer drug Xtandi scores new upbeat PhIII results

Medivation ($MDVN) and Astellas Pharma unveiled final results on primary and secondary efficacy endpoints from their Phase III PREVAIL trial of Xtandi (enzalutamide), showing that the drug delayed tumor growth and prolonged the lives of patients with metastatic prostate cancer who previously have not undergone chemotherapy. The new data could open up more potential uses for Xtandi, which was approved in 2012 for metastatic prostate cancer in men who had already been treated with the chemo drug docetaxel. More from FiercePharma

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.